PHILADELPHIA, Aug. 2, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced that Marshall ('Mac') D. Deweese, who has more than fifteen years of experience in blood glucose monitoring systems, has joined Echo Therapeutics' management team as part of the company's plan to accelerate the development of the Symphony System and other new products in the Company's growth strategy.
Marshall Deweese joins as Vice President of Operations overseeing Echo's product development, engineering, manufacturing, regulatory and quality functions and reports directly to Kenneth Gary who was recently appointed Senior Vice President, Research and Operations.
"Mac's significant experience in product development, management, and manufacturing of diabetes management systems will ensure the successful clinical validation and product launch of our Symphony tCGM System," said Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics. "We are dedicated to adding to our already deep domain expertise and we are excited to have such a seasoned diabetes care veteran join Echo Therapeutics at such a critical time as we move toward our goal of FDA marketing clearance of Symphony."
Mr. Deweese has 16 years of experience with Abbott Laboratories (formerly MediSense) in the technical product development, program management, and mass manufacture of portable glucose meters. As the Director of R & D, Program Management, and OEM Operations at Abbott Laboratories, Mr. Deweese led the industrial design, mechanical engineering, and manufacturing preparation of handheld portable glucose meters. As the Vice President and co-founder of Massachusetts Technology Associates (Mass Tech), Mr. Deweese provided engineering and manufacturing services to its client base, specializing in high quality, rapid turnaround prototype and assembly services. Mr. Deweese studied engineering at Massachusetts Institute of Technology.
About Echo Therapeutics
Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.
Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2010, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.
For More Information:
Christine H. Olimpio
Director, Corporate Communications
Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx
SOURCE Echo Therapeutics, Inc.